Online training (28–29 April 2026) on immunogenicity of biologics and ATMPs, covering ADA risk assessment, bioanalytical assays, and evolving EMA/FDA expectations to reduce development and regulatory risk.

Regulators are tightening global expectations for extractables and leachables under draft ICH Q3E, shifting E&L to a lifecycle risk priority. Fleming’s March 2026 training helps industry apply risk-based, compliant E&L strategies.